Resisting Resistance: Targeted Therapies in Lung Cancer. - Wikidata - awgldk - TriplyDB

Resisting Resistance: Targeted Therapies in Lung Cancer.

Resisting Resistance: Targeted Therapies in Lung Cancer.

http://www.wikidata.org/entity/Q37388238

about

Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axis Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer.Recent Advances in Targeting ROS1 in Lung Cancer.Targeting ALK: Precision Medicine Takes on Drug Resistance.Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.Integrated analysis profiles of long non-coding RNAs reveal potential biomarkers of drug resistance in lung cancer.Current Landscape of Targeted Therapy in Lung Cancer.Inhibition of aldehyde dehydrogenase 1 enhances the cytotoxic effect of retinaldehyde on A549 cancer cells.Oncogene-Driven Metabolic Alterations in Cancer.The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro.YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting.Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells

P2860

Q33823065-C190D1AC-B260-424B-889D-ACA0F97ACC37 Q33830016-218CEA5E-B977-4AFD-BA75-BFB5B7F4B39D Q38430613-17980AF0-CB52-45CE-93F3-7A49F578687A Q38640765-EF0F4ADA-938B-4732-B072-BF039DBAC7B3 Q39103431-1EE1B349-101C-49B9-9BBA-DCDBEA56CA43 Q41605016-488578B7-93F7-43C6-A021-05A21A99D2A2 Q41846396-BABD3FD1-8755-43B6-B2B5-5FF6CE74E236 Q46034707-DC65F5DF-7496-4F73-90DF-4B38D9E15B66 Q46238891-6A526C2D-9EFB-4AD5-9D82-CC1462F41DD2 Q47159555-0C1412E5-5BF7-4738-96F0-C118E85D6A29 Q49913969-8DB517AF-2335-46C0-9B3D-D4C4286068EE Q53686708-3A1F8938-7407-4D2D-9554-A0173FBDC50D Q59125598-F641254D-7C98-4128-AD49-C9E1D61C45C6

P2860

Resisting Resistance: Targeted Therapies in Lung Cancer.

http://www.wikidata.org/entity/Q37388238

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Resisting Resistance: Targeted Therapies in Lung Cancer.

@en

Resisting Resistance: Targeted Therapies in Lung Cancer.

@nl

type

label

Resisting Resistance: Targeted Therapies in Lung Cancer.

@en

Resisting Resistance: Targeted Therapies in Lung Cancer.

@nl

prefLabel

Resisting Resistance: Targeted Therapies in Lung Cancer.

@en

Resisting Resistance: Targeted Therapies in Lung Cancer.

@nl

P1433

Q37388238-5727368B-3408-4CF4-921D-FEC4D9582E65

P1476

Q37388238-80B5A6E2-AB78-492C-AE25-C3952918D49F

P2093

Q37388238-60E82B19-83E1-461F-BF9B-B1E8974FBD86

Q37388238-B6987C39-8C2D-4B52-8C87-D5EE611BF101

P2860

Q37388238-02BD16B4-45BC-448B-9594-1667F45C5055

Q37388238-04F81FF3-470B-46AA-AF26-26DCC4203C38

Q37388238-059ECB2F-30E0-4BAB-9EA0-025FF3FEA037

Q37388238-070C8A17-6A5F-4F98-8FB2-95F02B32D6A9

Q37388238-0D743356-C89C-4E3A-ABBE-8436EDA73897

Q37388238-0DD97D2D-4E1F-4443-A278-E7DCFE999ABB

Q37388238-147BEF84-5B80-4C60-B559-820EF62DDCC2

Q37388238-1B638D6E-E184-4E4A-9754-9B53F7ADBD2C

Q37388238-1EA03192-B16F-4A48-A066-72E6E434A856

Q37388238-27056AF1-55FA-42DC-A42B-DD02E21DC05A

P304

Q37388238-D7EE5D50-32A6-48AB-A93A-4B21014CE7DF

P31

Q37388238-28BA87EA-7EFC-4D34-92E3-0D203076D78D

P356

Q37388238-C33961E4-4AB6-40FE-BF60-684A75585C7A

P433

Q37388238-2FDF0C77-7EF3-4B51-A9F9-7B63B8B1F936

P478

Q37388238-B9666DDF-A0C2-453D-B45B-1A81660A8857

P577

Q37388238-471A8D85-02AD-497A-990F-C4FDB8C22218

P698

Q37388238-D1ECE7DA-6205-447E-BD62-937331E3D24A

P932

Q37388238-7D83973C-3C57-46C0-B098-BE97BA0C090F

P356

J.TRECAN.2016.05.010

P1433

Trends in cancer

P1476

Resisting Resistance: Targeted Therapies in Lung Cancer.

@en

P2093

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Jessica J Lin

http://www.w3.org/2001/XMLSchema#string

P2860

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

ROS1 rearrangements define a unique molecular class of lung cancers.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

P304

350-364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRECAN.2016.05.010

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27819059

http://www.w3.org/2001/XMLSchema#string

P932

5091655

http://www.w3.org/2001/XMLSchema#string